Harmony Biosciences stock hits 52-week high at $42.70

Harmony Biosciences (HRMY) stock achieved a remarkable 52-week high of $42.70, indicating a notable milestone for the company. The current trading price stands at $42.72, with a market capitalization of $2.49 billion. Over the past year, HRMY's stock has shown a positive change of 13.59%, reflecting accelerating momentum over the six-month period.

InvestingPro analysis suggests the stock is undervalued, with a Fair Value of $59.06, hinting at potential upside for investors. The company's EXCELLENT financial health score of 3.89 underscores investor confidence and suggests promising growth in its operations. This progress was observed amidst market fluctuations, emphasizing Harmony Biosciences' resilience and strategic positioning within the biosciences sector.

The company reported a 24% revenue growth, accompanied by a P/E ratio of 13.77. Analysts forecast continued profitability this year, supported by positive earnings reports and positive outlooks from Wall Street. Harmony Biosciences surpassed expectations in second-quarter 2026 earnings, delivering an adjusted profit of $1.28 per share, compared to analysts' estimate of 87.89 cents.

The company's Wakix product generated record net revenue of $261.3 million, exceeding the consensus estimate of $250.8 million. HRMY reaffirmed its full-year revenue guidance, projecting between $1.00 billion and $1.04 billion. Wall Street firms have shown confidence in HRMY, with Wolfe Research initiating coverage with an Outperform rating and a price target of $60.00, and Oppenheimer adjusting its price target to $70 from $85, maintaining an Outperform rating.

Despite challenges such as intellectual property litigation and competition from orexin agonists, HRMY remains optimistic, projecting Wakix to achieve $1 billion in sales by 2026. The company's progress in its BP-205 orexin-2 program was highlighted during their recent earnings call. These developments illustrate a dynamic period for Harmony Biosciences as it navigates opportunities and challenges within the market.